Rev.1 Engineering

Rev.1 Engineering is a U.S.-based medical device development and early manufacturing company serving startups and established OEMs in the medtech sector. The company provides end-to-end support spanning concept development, engineering, prototyping, testing, design controls, validation, and low-volume cleanroom manufacturing for complex first-of-kind devices. Its technical focus is on minimally invasive and interventional products across areas such as structural heart, interventional cardiology, electrophysiology, gastrointestinal, oncology, neuromodulation, and combination products. Rev.1 appears to operate primarily as a services and platform-enablement partner rather than a therapeutics developer with an internal drug pipeline. The company was acquired by Asahi Intecc in 2021 and continues to operate under the Rev.1 Engineering name.